# N4 Pharma Make considerable progress on Nuvec, well positioned for collaborations (Interview)

- Link: https://www.directorstalkinterviews.com/n4-pharma-make-considerable-progress-on-nuvec-well-positioned-for-collaborations/412963831
- Published: 2021-02-25T08:05:27+00:00
- Author: Giles

**N4 Pharma Plc** (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss results
for the year ended 31 December 2020. Nigel talks us through the highlights of the
year, updates us on the new refined strategy to focus on three work streams, explains
what the Patent in relation to Nuvec means for the company and lets us know what
investors can expect from N4 Pharma in the near future.

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system
for cancer and vaccine treatments using its unique silica nanoparticle delivery 
system called Nuvec®.

The business model is to partner with companies developing novel antigens for cancer
and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen
into cells to express the protein needed for the required immunity. As these products
progress through pre clinical and clinical programs, the company will seek to receive
upfront payments, milestone payments and ultimately royalty payments once products
reach the market.

Share on: